ReviewPharmacological reviews2013
Idiosyncratic adverse drug reactions: current concepts.
Review in Pharmacological reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 2 syntheses or guidelines pooled it, 308 citations in OpenAlex.
- Angiotensin-Converting Enzyme Inhibitor-Drug Induced Liver Injury: Clinical Features and Diagnostic Features - A Systematic Review of Current Reported Cases.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025Pooled it
- Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions.Clinical pharmacology and therapeutics · 2019Pooled it
- Combined immune modulation reveals carbamazepine-associated CD8Archives of toxicology · 2026Article
- Enhancing anandamide signalling through fatty acid amide hydrolase inhibition: An update on the pharmacological strategy for treating psychiatric disorders.Translational psychiatry · 2026Review
- A pharmacist-led framework for antibiotic-associated liver injury: from pharmacovigilance signals to bedside surveillance with the updated RUCAM and susceptibility markers.Frontiers in pharmacology · 2026Review
- Identification of potential COVID-19 Mpro inhibitors through covalent drug docking, molecular dynamics simulation, and MMGBSA calculation.Scientific reports · 2025Article
- Ceftriaxone-Induced Pancytopenia: A Case Report.Hematology reports · 2025Article
- Artificial Intelligence (AI) and Drug-Induced and Idiosyncratic Cytopenia: The Role of AI in Prevention, Prediction, and Patient Participation.Hematology reports · 2025Review
- Drug-Induced Liver Injury-Pharmacological Spectrum Among Children.International journal of molecular sciences · 2025Review
- Case Report: Fatal presumptive idiosyncratic hepatic necrosis secondary to standard-dose leflunomide administration in a dog.Frontiers in veterinary science · 2025Article
- Insights into regulatory T-cell and type-I interferon roles in determining abacavir-induced hypersensitivity or immune tolerance.Frontiers in immunology · 2025Article
- Detection and Quantification of Drug-Protein Adducts in Human Liver.Journal of proteome research · 2024Article
- Selective HLA Class II Allele-Restricted Activation of Atabecestat Metabolite-Specific Human T-Cells.Chemical research in toxicology · 2024Article
- Precious Cargo: The Role of Polymeric Nanoparticles in the Delivery of Covalent Drugs.Molecules (Basel, Switzerland) · 2024Review
- The use of PD-1 functional knockout rats to study idiosyncratic adverse reactions to nevirapine.Toxicological sciences : an official journal of the Society of Toxicology · 2024Article
- Evaluation of the protective effect of losartan in acetaminophen-induced liver and kidney damage in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Protein Haptenation and Its Role in Allergy.Chemical research in toxicology · 2024Review
- Super-refractory status epilepticus, rhabdomyolysis, central hyperthermia and cardiomyopathy attributable to spinal anesthesia: a case report and review of literature.BMC anesthesiology · 2024Review
- In vitro and in vivo metabolic activation and hepatotoxicity of chlorzoxazone mediated by CYP3A.Archives of toxicology · 2024Article
- Phytochemistry, pharmacology, toxicology and detoxification ofFrontiers in pharmacology · 2024Review
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Idiosyncratic drug reactions are a significant cause of morbidity and mortality for patients; they also markedly increase the uncertainty of drug development. The major targets are skin, liver, and bone marrow. Clinical characteristics suggest that IDRs are immune mediated, and there is substantive evidence that most, but not all, IDRs are caused by chemically reactive species. However, rigorous mechanistic studies are very difficult to perform, especially in the absence of valid animal models. Models to explain how drugs or reactive metabolites interact with the MHC/T-cell receptor complex include the hapten and P-I models, and most recently it was found that abacavir can interact reversibly with MHC to alter the endogenous peptides that are presented to T cells. The discovery of HLA molecules as important risk factors for some IDRs has also significantly contributed to our understanding of these adverse reactions, but it is not yet clear what fraction of IDRs have a strong HLA dependence. In addition, with the exception of abacavir, most patients who have the HLA that confers a higher IDR risk with a specific drug will not have an IDR when treated with that drug. Interindividual differences in T-cell receptors and other factors also presumably play a role in determining which patients will have an IDR. The immune response represents a delicate balance, and immune tolerance may be the dominant response to a drug that can cause IDRs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.